AUSTRALIAN companies Arrotex Pharmaceuticals and George Medicines have partnered to support the commercialisation of an innovative therapy designed for the management of hypertension in adults.
The new therapy is the culmination of more than 20 years of medical research focused on improving prevention, control and management of hypertension, and aims to address low adherence to regimens involving multiple medicines.
Under the agreement, Arrotex will oversee regulatory engagement, market access strategy, commercialisation planning and national distribution, while George Medicines will support product advancement through access to its proprietary technology and clinical expertise.
The partnership enables early commercial planning for the treatment and its potential availability for clinicians and patients in Australia and New Zealand as early as next year.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Mar 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Mar 26
